Umbilical cord stem cell vesicles protect islet grafts in diabetic mice

Islet transplantation can be limited by early graft injury and beta-cell loss. Researchers tested extracellular vesicles from human umbilical cord mesenchymal stem cells (hucMSC-EVs) in a syngeneic islet-transplant model using streptozotocin-induced diabetic mice. They also studied primary islets and beta cells exposed to endoplasmic reticulum stress in laboratory experiments. The abstract does not report the number of animals or islets used per group.

Co-transplantation of hucMSC-EVs with 250 islet equivalents improved glycaemic control and glucose tolerance compared with grafts without EVs (both p<0.01). Grafts receiving EVs had fewer apoptotic beta cells, while laboratory assays found preserved insulin expression and glucose-stimulated insulin secretion. Mechanistic experiments implicated EV-enriched miR-182-5p, which targeted XBP1 and was associated with restored calcium homeostasis and mitochondrial function. Depleting miR-182-5p removed the reported protective effects in mice.

These findings suggest a potential cell-free approach to protecting islet grafts, but the evidence is preclinical. The study does not establish safety, efficacy, or a role for hucMSC-EVs in human transplantation; clinical benefit cannot be inferred from these mouse and cell experiments.